Given that the pathophysiology of PCOS is rooted in insulin resistance,
insulin-sensitizing agents have proven to be beneficial in improving metabolic
abnormalities. Newer classes of antidiabetic agents, such as glucagon-like peptide-1
(GLP-1) receptor agonists (GLP1RA), dipeptidyl peptidase IV (DPP IV) inhibitors, and
sodium-glucose transport protein 2 (SGLT2) inhibitors, are being investigated for the
treatment of PCOS. They have advantageous impacts on body weight, cardiovascular
health, and antihyperglycemic effects and might be an intriguing therapeutic addition to
the PCOS repertoire. Other drugs in the pipeline include statins and phosphodiesterase4 inhibitors (PDE4 inhibitors). The ongoing studies on the roles of clomiphene,
aromatase inhibitors, and bromocriptine in reproductive function hold enormous
promise and have shown potential as therapeutic strategies to be employed in the
administration of PCOS-related reproductive complications.
Keywords: Aromatase inhibitors, Bromocriptine, Clomiphene, Dipeptidyl peptidase IV (DPP IV) inhibitors, Glucagon-like peptide-1 (GLP-1) receptor agonists, Insulin resistance, Obesity, Phosphodiesterase-4 inhibitors (PDE4 inhibitors), Polycystic ovary syndrome, Statins, Sodium-glucose transport protein 2 (SGLT2) inhibitors.
